In this video, Shebli Atrash, MD, Levine Cancer Institute, Charlotte, NC, briefly discusses the prognostic value of the Ki-67 index in patients with newly diagnosed multiple myeloma (NDMM) and highlights the value of using this index to improve currently used staging systems. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.